Investor Presentaiton

Investor presentation First three months of 2017 Solid US market share within the modern and new generation insulin segment Insulin market by segments in the US Slide 43 Device penetration tMU 160 140 120 Fast-acting 100 80 Premix 60 40 20 Modern Insulin penetration CAGR volume¹: 2.3% Penetration CAGR value¹: 27.1% Novo Nordisk MI and NGI volume market shares in the US Sanofi Eli Lilly 60% 100% 50% 80% 40% 40% 38% 60% 30% 40% 20% 22% Long-acting 20% 10% 0% 0% Feb 2012 Feb 2017 Feb 2012 Feb 2017 1 CAGR for 5-year period Source: IMS Monthly MAT February, 2017 volume and value (DKK) figures changing diabetes® Source: IMS Monthly MAT February, 2017 volume figures novo nordisk

View entire presentation